CellaVision
224,5 SEK +2,05%1.506 investorer følger denne virksomhed
CellaVision is active in medical technology. The company's operations develop and market image analysis systems for diagnosing blood and other body fluids. The products are intended to replace traditional microscope analysis. Operations are conducted on a global level, primarily in the Nordic countries, Europe and North America, where customers consist of research institutes. The head office is located in Lund.
Omsætning
677,29 mio.
EBIT %
24,66 %
P/E
41,12
Udbytteafkast, %
1 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
CEVI
Daglig lav / høj pris
215 / 224,5
SEK
Markedsværdi
5,35 mia. SEK
Aktieomsætning
1,41 mio. SEK
Volumen
6,4 t
Seneste videoer
Finanskalender
Delårsrapport
25.04.2024
Generalforsamling
03.05.2024
Årligt udbytte
06.05.2024
Delårsrapport
19.07.2024
Delårsrapport
24.10.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
William Demant Invest | 19,9 % | 19,9 % |
Grenlunden CEVI AB | 10,0 % | 10,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
CellaVision publishes its 2023 Annual and Sustainability Report
CellaVision, Audiocast with teleconference, Q1, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools